GlassScriptPhysician profile
Glen E Vanderzalm
NPI 1528033578
$3,320.95
in general payments reported to CMS, 2019-2025
25 companies · $431 in 2025
The $431 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $152 · 2021: $377 · 2022: $301 · 2023: $617 · 2024: $1,055 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,101.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,415.25 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Pfizer INC. | $456.78 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $318.89 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $155.89 | 2019-2024 | Stelara |
| Intercept Pharmaceuticals, INC. | $132.65 | 2021-2025 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.47 | 2019-2024 | Xifaxan, Plenvu |
| Phathom Pharmaceuticals, INC. | $98.67 | 2024-2025 | Voquezna |
| Celgene Corporation | $93.39 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $74.23 | 2021-2023 | |
| Vivus LLC | $62.27 | 2024-2025 | Pancreaze |
| Redhill Biopharma INC. | $54.36 | 2023-2024 | Talicia, Aemcolo |
| Medtronic, INC. | $41.47 | 2021 | |
| Fresenius Kabi USA, LLC | $41.09 | 2023 | Idacio |
| Evoke Pharma, INC. | $34.64 | 2023 | Gimoti |
| Madrigal Pharmaceuticals | $28.80 | 2024 | Resmetirom |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $26.10 | 2023 | Amjevita, Avsola |
| Daiichi Sankyo INC. | $24.73 | 2022 | |
| Braintree Laboratories, INC. | $23.28 | 2024 | Sutab, Suflave |
| Aimmune Therapeutics, INC. | $23.11 | 2024 | |
| Merck Sharp & Dohme LLC | $22.37 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $21.60 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $17.78 | 2019 | |
| Capsovision, INC. | $17.32 | 2023 | Capsocam Plus |
| Ethicon US, LLC | $16.07 | 2019 | |
| Allergan, INC. | $14.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Vanderzalm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.